Trial Profile
A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once Every 2 Weeks in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2017
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Onconova Therapeutics
- 29 Jun 2017 NCT01326377 is an obsolete identifier of NCT00906334
- 26 Feb 2014 The dosing regimen has been changed; primary endpoint 'number of patients with adverse events' has been added.
- 26 Feb 2014 The dosing regimen has been changed; primary endpoint 'number of patients with adverse events' has been added.